@article{23569f248a2d4265b8ec2e966334d858,
title = "Matrix metalloproteinase-9 in an exploratory trial of intravenous minocycline for acute ischemic stroke",
abstract = "Background and Purpose-Plasma matrix metalloproteinase-9 levels predict posttissue plasminogen activator (tPA) hemorrhage. Methods-The authors investigated the effect of minocycline on plasma matrix metalloproteinase-9 in acute ischemic stroke in the Minocycline to Improve Neurological Outcome in Stroke (MINOS) trial and a comparison group. Results-Matrix metalloproteinase-9 level decreased at 72 hours compared with baseline in MINOS (tPA, P=0.0022; non-tPA, P=0.0066) and was lower than in the non-MINOS comparison group at 24 hours (tPA, P<0.0001; non-tPA, P=0.0019). Conclusions-Lower plasma matrix metalloproteinase-9 was seen among tPA-treated subjects in the MINOS trial. Combining minocycline with tPA may prevent the adverse consequences of thrombolytic therapy through suppression of matrix metalloproteinase-9 activity.",
keywords = "acute stroke, inflammation, neuroprotection",
author = "Switzer, \{Jeffrey A.\} and Hess, \{David C.\} and Adviye Ergul and Waller, \{Jennifer L.\} and MacHado, \{Livia S.\} and Vera Portik-Dobos and Pettigrew, \{L. Creed\} and Clark, \{Wayne M.\} and Fagan, \{Susan C.\}",
year = "2011",
month = sep,
doi = "10.1161/STROKEAHA.111.618215",
language = "English",
volume = "42",
pages = "2633--2635",
number = "9",
}